https://www.aigom.it/wp-content/uploads/2024/04/ANONCOL.png12441097Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-04-18 12:22:432024-04-23 08:17:23EVENT-FREE SURVIVAL BY RESIDUAL CANCER BURDEN WITH PEMBROLIZUMAB IN EARLY-STAGE TRIPLE NEGATIVE BREAST CANCER (TNBC): EXPLORATORY ANALYSIS FROM KEYNOTE-522
https://www.aigom.it/wp-content/uploads/2024/04/art16.4a.png21701963Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-04-15 08:41:542024-04-15 08:54:31DOSTARLIMAB FOR PRIMARY ADVANCED OR RECURRENT ENDOMETRIAL CANCER.
https://www.aigom.it/wp-content/uploads/2024/04/art.9.4.png821663Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-04-05 07:37:332024-04-11 07:58:10ENFORTUMAB VEDOTIN AND PEMBROLIZUMAB IN UNTREATED ADVANCED. UROTHELIAL CANCER
https://www.aigom.it/wp-content/uploads/2024/03/lan.articolo.png911927Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-03-22 07:12:532024-03-22 07:18:33NANOLIPOSOMAL IRINOTECAN WITH FLUOROURACIL AND FOLINIC ACID IN METASTATIC PANCREATIC CANCER AFTER PREVIOUS GEMCITABINE-BASED THERAPY (NAPOLI-1): A GLOBAL, RANDOMISED, OPEN-LABEL, PHASE 3 TRIAL
https://www.aigom.it/wp-content/uploads/2024/03/jco8.3.png869923Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-03-08 08:09:282024-03-08 08:09:28EFFECT OF HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY ON CYTOREDUCTIVE SURGERY IN GASTRIC CANCER WITH SYNCHRONOUS PERITONEAL METASTASES: THE PHASE III GASTRIPEC-I TRIAL
https://www.aigom.it/wp-content/uploads/2024/02/ARTICOLO-15feb.jpg821581Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2024-02-15 15:00:492024-02-15 15:00:49ATEZOLIZUMAB CON O SENZA RADIOTERAPIA PER IL CARCINOMA SQUAMOSO AVANZATO DEL PENE (STUDIO PERICLES): TRIAL DI FASE II
https://www.aigom.it/wp-content/uploads/2024/02/ARTICOLO-9febb.jpg821581Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2024-02-09 13:42:322024-02-09 13:43:30STUDIO KATHERINE: T-DM1 adiuvante vs trastuzumab per EBC HER2+ con malattia residua dopo terapia neoadiuvante (chemioterapia e anti-HER2). Analisi finale della IDFS e seconda interim analisi della OS.
